Treatment with a finerenone-empagliflozin combo leads to greater decreases in albuminuria in CKD and type 2 diabetes.
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
A study highlights the role of NPT2b in tubulointerstitial fibrosis and CKD progression.
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis.
A study assessed whether the cardiovascular and renal effects of canagliflozin are dose dependent.
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Survival benefits of deceased-donor kidney transplantation decrease when older patients receive lower quality organs.
Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.
Advertisement
Expert Interviews
In Print
NKF SCM25, osteoporosis with lupus nephritis, kidney transplant with HIV, dialytrauma, payment for phosphate binders, more.
World Congress of Nephrology 2025, rare kidney disease, renal nutrition, GLP-1 receptor agonists, and more.
Conferences
The annual nephrology meeting organized by the European Renal Association
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
Podcasts
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Listen to the discussion of Chapter 18 of Dr. Burton Rose's book, focused on metabolic alkalosis.
Freely Filtered returns with another episode for NephMadness, this time, covering the hemodialysis region.
Expert Columns
Ajay Singh talks dialytrauma—harmful effects of dialysis in patients with AKI moving from inpatient to outpatient care.
Sarah Tolson reviews how changes to reimbursement for phosphate binders have affected dialysis programs.
Ajay Singh discusses the state of rare kidney disease research.
Sarah Tolson highlights the concerns and challenges dialysis programs face under the 2025 ESRD PPS requirements.
Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.
Sarah Tolson shares what billing departments of dialysis programs need to know about the CMS final rule for the ESRD PPS.
Knowledge Hubs
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.